Sam Rougas, MD
Cardiovascular Disease · Denver, CONPI 1649416843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,616 and has fallen 68.9% since, to $503 in 2025.
Across 278 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$868
- Novartis$523
- Sanofi-aventis U.S. LLC$378
- Amgen$351
- Boston Scientific$317
- Boehringer Ingelheim$317
- plus $4K from 37 others
Across 3 payments — averaging $12,545 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$38K
What the payments were for
- Consulting fees$260%
- Food & beverage$6,13997%
- Education$1743%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$274
- Barostim Neo System$146
- XARELTO$139
- WATCHMAN Access System$138
- MitraClip$136
- Ozempic$116
- Watchman$114
How this compares
$6,339 in reported general payments places this provider in the 80th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 211 | $260,633 |
| VyndamaxTafamidis | 11 | $242,484 |
| XareltoRivaroxaban | 59 | $63,851 |
| FarxigaDapagliflozin Propanediol | 33 | $51,555 |
| EntrestoSacubitril/Valsartan | 18 | $33,331 |
| JardianceEmpagliflozin | 19 | $31,017 |
| MultaqDronedarone Hcl | 13 | $20,115 |
| Repatha SureclickEvolocumab | 18 | $14,265 |
| Praluent PenAlirocumab | 15 | $7,593 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $5,607 |
| Metoprolol Succinate | 158 | $2,392 |
| Carvedilol | 165 | $1,851 |
| Rosuvastatin Calcium | 121 | $1,632 |
| Ezetimibe | 60 | $1,475 |
| Potassium Chloride | 30 | $1,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $868 | $503,117222 claims |
| Johnson & JohnsonXarelto | $306 | $63,85159 claims |
| AstraZenecaFarxiga | $316 | $51,55533 claims |
| NovartisEntresto | $523 | $33,33118 claims |
| Boehringer IngelheimJardiance | $317 | $31,01719 claims |
| Sanofi-aventis U.S. LLCMultaq | $378 | $20,11513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Denver
- Andrew FreemanDenver$454K
- Sameer MehtaDenver$92K
- Jake ChaninDenver$82K
- John RumsfeldDenver$24K
- Mori KrantzDenver$22K
- Fady IskanderDenver$16K
- Jose SanchezDenver$8K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- William SauerAurora$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.